Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients.

Journal

Cell & bioscience
ISSN: 2045-3701
Titre abrégé: Cell Biosci
Pays: England
ID NLM: 101561195

Informations de publication

Date de publication:
21 Nov 2021
Historique:
received: 05 11 2021
accepted: 13 11 2021
entrez: 22 11 2021
pubmed: 23 11 2021
medline: 23 11 2021
Statut: epublish

Résumé

There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for immunocompromised patients. In this study, we determined the neutralizing antibody response in 160 cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin's lymphomas (NHL), after they received two doses of mRNA vaccines. Serum from 46 mRNA vaccinated health care workers (HCWs) served as healthy controls. We discovered that (1) cancer patients exhibited reduced neutralizing antibody titer (NT

Identifiants

DOI: 10.1186/s13578-021-00713-2 PMID: 34802457 PMC: PMC8606166
pubmed: 34802457
doi: 10.1186/s13578-021-00713-2
pii: 10.1186/s13578-021-00713-2
pmc: PMC8606166
doi:

Types de publication

Letter

Langues

eng

Pagination

197

Subventions

Organisme : NCI NIH HHS
ID : U54CA260582
Pays : United States
Organisme : NIH HHS
ID : HL127442-01A1
Pays : United States
Organisme : NIH HHS
ID : NIH RO1 AI150473
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016058
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150473
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2021. The Author(s).

Références

Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34117117
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
mBio. 2021 Oct 26;12(5):e0251021
pubmed: 34607452
JCI Insight. 2020 Nov 19;5(22):
pubmed: 33035201
Cancer Cell. 2021 Aug 9;39(8):1031-1033
pubmed: 34331856
J Hepatol. 2021 Aug;75(2):435-438
pubmed: 33892006
Int J Clin Oncol. 2020 May;25(5):790-800
pubmed: 31900651
N Engl J Med. 2021 Sep 30;385(14):1330-1332
pubmed: 34469645

Auteurs

Cong Zeng (C)

Center for Retrovirus Research, The Ohio State University, Columbus, OH, 43210, USA.
Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, 43210, USA.

John P Evans (JP)

Center for Retrovirus Research, The Ohio State University, Columbus, OH, 43210, USA.
Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, 43210, USA.
Molecular, Cellular and Developmental Biology Program, The Ohio State University, 43210, Columbus, OH, USA.

Sarah Reisinger (S)

Comprehensive Cancer Center, James Cancer Hospital, The Ohio State University, Columbus, OH, 43210, USA.

Jennifer Woyach (J)

Division of Hematology, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.

Christina Liscynesky (C)

Internal Medicine, Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University, Columbus, OH, 43210, USA.

Zeinab El Boghdadly (ZE)

Internal Medicine, Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University, Columbus, OH, 43210, USA.

Mark P Rubinstein (MP)

Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA.

Karthik Chakravarthy (K)

Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA.

Linda Saif (L)

Center for Food Animal Health, Animal Sciences Department, OARDC, College of Food, Agricultural and Environmental Sciences,, Wooster, OH, 44691, USA.
Veterinary Preventive Medicine Department, College of Veterinary Medicine, The Ohio State University, 44691, Wooster, OH, USA.
Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, OH, 43210, USA.

Eugene M Oltz (EM)

Department of Microbial Infection and Immunity, The Ohio State University, 43210, Columbus, OH, USA.

Richard J Gumina (RJ)

Department of Medicine, The Ohio State University, Columbus, OH, 43210, USA.

Peter G Shields (PG)

Comprehensive Cancer Center, James Cancer Hospital, The Ohio State University, Columbus, OH, 43210, USA. Peter.Shields@osumc.edu.

Zihai Li (Z)

Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA. Zihai.Li@osumc.edu.

Shan-Lu Liu (SL)

Center for Retrovirus Research, The Ohio State University, Columbus, OH, 43210, USA. Liu.6244@osu.edu.
Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, 43210, USA. Liu.6244@osu.edu.
Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, OH, 43210, USA. Liu.6244@osu.edu.
Department of Microbial Infection and Immunity, The Ohio State University, 43210, Columbus, OH, USA. Liu.6244@osu.edu.
ORCID: 0000-0003-1620-3817

Classifications MeSH